Commercialization of nanotechnology
- PMID: 20049790
- DOI: 10.1002/wnan.28
Commercialization of nanotechnology
Abstract
The emerging and potential commercial applications of nanotechnologies clearly have great potential to significantly advance and even potentially revolutionize various aspects of medical practice and medical product development. Nanotechnology is already touching upon many aspects of medicine, including drug delivery, diagnostic imaging, clinical diagnostics, nanomedicines, and the use of nanomaterials in medical devices. This technology is already having an impact; many products are on the market and a growing number is in the pipeline. Momentum is steadily building for the successful development of additional nanotech products to diagnose and treat disease; the most active areas of product development are drug delivery and in vivo imaging. Nanotechnology is also addressing many unmet needs in the pharmaceutical industry, including the reformulation of drugs to improve their bioavailability or toxicity profiles. The advancement of medical nanotechnology is expected to advance over at least three different generations or phases, beginning with the introduction of simple nanoparticulate and nanostructural improvements to current product and process types, then eventually moving on to nanoproducts and nanodevices that are limited only by the imagination and limits of the technology itself. This review looks at some recent developments in the commercialization of nanotechnology for various medical applications as well as general trends in the industry, and explores the nanotechnology industry that is involved in developing medical products and procedures with a view toward technology commercialization.
(c) 2009 John Wiley & Sons, Inc.
Similar articles
-
Issues and concerns in nanotech product development and its commercialization.J Control Release. 2014 Nov 10;193:51-62. doi: 10.1016/j.jconrel.2014.06.005. Epub 2014 Jun 14. J Control Release. 2014. PMID: 24933600 Review.
-
Applying the marketing mix (5 ps) to bionanotechnology.Methods Mol Biol. 2011;726:393-411. doi: 10.1007/978-1-61779-052-2_25. Methods Mol Biol. 2011. PMID: 21424463
-
The economy of promises.Nat Nanotechnol. 2008 Feb;3(2):65-6. doi: 10.1038/nnano.2008.14. Nat Nanotechnol. 2008. PMID: 18654457 No abstract available.
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
-
Commercializing nanotechnology.Nat Biotechnol. 2003 Oct;21(10):1137-43. doi: 10.1038/nbt1003-1137. Nat Biotechnol. 2003. PMID: 14520392 No abstract available.
Cited by
-
Subchronic and chronic toxicity evaluation of inorganic nanoparticles for delivery applications.Adv Drug Deliv Rev. 2019 Apr;144:112-132. doi: 10.1016/j.addr.2019.07.006. Epub 2019 Jul 8. Adv Drug Deliv Rev. 2019. PMID: 31295521 Free PMC article. Review.
-
Cancer therapy with iron oxide nanoparticles: Agents of thermal and immune therapies.Adv Drug Deliv Rev. 2020;163-164:65-83. doi: 10.1016/j.addr.2020.06.025. Epub 2020 Jun 27. Adv Drug Deliv Rev. 2020. PMID: 32603814 Free PMC article.
-
Translation of nanotechnology-based implants for orthopedic applications: current barriers and future perspective.Front Bioeng Biotechnol. 2023 Aug 22;11:1206806. doi: 10.3389/fbioe.2023.1206806. eCollection 2023. Front Bioeng Biotechnol. 2023. PMID: 37675405 Free PMC article. Review.
-
Time-Dependent Growth of Silica Shells on CdTe Quantum Dots.Nanomaterials (Basel). 2018 Jun 16;8(6):439. doi: 10.3390/nano8060439. Nanomaterials (Basel). 2018. PMID: 29914152 Free PMC article.
-
Targeted drug delivery in neurodegenerative diseases: the role of nanotechnology.Front Med (Lausanne). 2025 Jan 29;12:1522223. doi: 10.3389/fmed.2025.1522223. eCollection 2025. Front Med (Lausanne). 2025. PMID: 39963432 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources